On this page
- Treatment of uncomplicated falciparum malaria
- Treatment of uncomplicated malaria due to other Plasmodium species, when chloroquine cannot be used
- Completion treatment following parenteral therapy for severe malaria
Forms and strengths
- 250 mg scored tablet
Dosage and duration
- Child 6 months and over (≥ 5 kg) and adult: 8 mg/kg once daily for 3 days (in combination with artesunate)
Contra-indications, adverse effects, precautions
- Do not administer to patients with neuropsychiatric disorders (or history of), seizures, hypersensitivity to mefloquine or quinine; mefloquine treatment in the previous 4 weeks.
- For completion treatment following parenteral therapy for severe malaria: do not administer if the patient developed neurological signs during the acute phase.
- May cause:
- gastrointestinal disturbances, dizziness, headache, sleeping disorders;
- more rarely: neuropsychiatric reactions, heart rhythm disorders, hypo or hypertension, skin allergies.
- If the patient vomits less than 30 minutes after administration, repeat the full dose. If the patient vomits within 30 to 60 minutes, re-administer a half the dose.
- Do not combine with anti-epileptics (risk of seizures), co-artemether, chloroquine (risk of seizures, cardiac toxicity).
- Do not administer simultaneously with quinine (risk of seizures, cardiac toxicity). If mefloquine is used after quinine IV, administer mefloquine 12 hours after the last dose of quinine.
- Administer with caution to patients taking antiarrhythmics, beta-blockers, calcium-channel blockers or digitalis (risk of heart rhythm disorders).
- Pregnancy: no contra-indication
- Breast-feeding: no contra-indication
- Also comes in co-formulated tablets containing artesunate 25 mg/mefloquine 50 mg and artesunate 100 mg/mefloquine 200 mg.
– Below 25 °C